SCHEMBL2704963

SCHEMBL2704963

c1ccc2c(c1)CCN2N1CCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
USP2 O75604 1/20 0.48
CDK4 P11802 1/20 0.48
ALOX15 P16050 1/20 0.48
CCND1 P24385 1/20 0.48
SIGMAR1 Q99720 2/20 0.46
NOTUM Q6P988 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TSHR P16473 2/20 0.42
HPGD P15428 1/20 0.41
MAPT P10636 3/20 0.40
MGLL Q99685 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
PTK2B Q14289 1/20 0.40
ESR2 Q92731 1/20 0.40
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2338480 0.98 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL10772899 0.90 SMN1; SMN2 (0.50) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL16823384 0.88 SMN1; SMN2 (0.49) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL3196430 0.82 HTR2C (0.45) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL6764695 0.76 SIGMAR1 (0.45) ALDH1A1MEN1KMT2ASIGMAR1NOTUM
SCHEMBL5872141 0.76 ALOX15 (0.46) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL27936706 0.75 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AUSP2CDK4
SCHEMBL8180438 0.75 OPRM1 (0.44) MAPTKDM4EESR2CHRM1
SCHEMBL28094982 0.75 HTR1A (0.51) ALDH1A1SIGMAR1TSHRHPGDKDM4E
SCHEMBL31218824 0.73 CHRM2 (0.39) ALDH1A1MEN1KMT2AUSP2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230113944-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-04-13 US disclosed
EP-4087847-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES The Regents of the University of California (US) 2022-11-16 EP disclosed
US-20180271924-A1 COMPOUND AND METHOD FOR REDUCING INFLAMMATION, PAIN, ALLERGY, FLU AND COLD SYMPTOMS KARIMAN ALEXANDER (US) 2018-09-27 US disclosed
CN-106632388-A Naturally active drug intermediate with high biological activity and preparation method thereof 胡寅俊 2017-05-10 CN disclosed
CN-106632388-A Naturally active drug intermediate with high biological activity and preparation method thereof 胡寅俊 2017-05-10 CN disclosed
CN-104274441-B Application of selaginella tamariscina alkaloid in preparation of medicine for treating thrombotic diseases 中国药科大学 2017-01-11 CN disclosed
CN-104274441-A Application of selaginella tamariscina alkaloid in preparation of medicine for treating thrombotic diseases UNIV CHINA PHARMA 2015-01-14 CN disclosed
EP-1715863-B1 ENHANCEMENT OF AMPAKINE-INDUCED FACILITATION OF SYNAPTIC RESPONSES BY CHOLINESTERASE INHIBITORS CORTEX PHARMA INC (US) 2012-05-09 EP disclosed
EP-1715863-A4 ENHANCEMENT OF AMPAKINE-INDUCED FACILITATION OF SYNAPTIC RESPONSES BY CHOLINESTERASE INHIBITORS CORTEX PHARMA INC (US) 2009-03-25 EP disclosed
EP-1715863-A2 ENHANCEMENT OF AMPAKINE-INDUCED FACILITATION OF SYNAPTIC RESPONSES BY CHOLINESTERASE INHIBITORS CORTEX PHARMACEUTICALS, INC. (US) 2006-11-02 EP disclosed
US-20050228019-A1 Enhancement of ampakine-Induced facilitation of synaptic responses by cholinesterase inhibitors CORTEX PHARMACEUTICALS, INC. (US) 2005-10-13 US disclosed
WO-2005072345-A2 ENHANCEMENT OF AMPAKINE-INDUCED FACILITATION OF SYNAPTIC RESPONSES BY CHOLINESTERASE INHIBITORS CORTEX PHARMACEUTICALS INC. (US) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113944-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SMPD2, PSEN2, SMN1; SMN2 ALDH1A1 2902/4885MEN1 3433/4885KMT2A 1895/4885
US-20050228019-A1 Enhancement of ampakine-Induced facilitation of synaptic responses by cholinesterase inhibitors GRIK1, GRIK2, GRIK4 ALDH1A1 2582/4885MEN1 4505/4885KMT2A 1737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.